Faron Pharmaceuticals Oy (FARN) Price & Analysis

Compare

44 Followers

FARN Stock Chart & Stats

170.00p

-2.73p(-1.37%)

At close: Jan 09 4:00 PM EST

170.00p

-2.73p(-1.37%)

Day’s Range― - ―

52-Week Range146.00p - 270.00p

Previous CloseN/A

Volume750.00

Average Volume (3M)46.62K

Market Cap

£195.43M

Enterprise Value270.38M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Mar 04, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding114,420,460

10 Day Avg. Volume70,409

30 Day Avg. Volume46,616

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,000.00

Price Target Upside488.24% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyThe combination therapy reached an objective response rate of 64% with a median overall survival of 14.5 months in refractory or relapsed high-risk myelodysplastic syndrome patients.

Regulatory ApprovalFaron plans to engage regulators to pursue a Phase 2/3 registrational program with potential for accelerated approval in both frontline and relapsed/refractory MDS.

Safety And DifferentiationSafety remains favorable, with 36% of treatment-emergent adverse events related to Bex, and no Grade 5 events, further differentiating Bex from other approaches such as the Bcl-2 inhibitor venetoclax.

Bears Say

Clinical Development RiskThere are several risks associated with the stock including clinical development risk, competitor risk, and commercialization risk.

Valuation RisksValuation assumes risks such as clinical development risk, competitor risk, novel Clever-1 mechanism risk, commercialization risk, reimbursement risk, pricing risk, business development risk, and capital market and dilution risk.

Faron Pharmaceuticals Oy News

Faron Pharmaceuticals Revises Shareholders’ Nomination Board Composition

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an update. Faron Pharmaceuticals Ltd has announced the re-election of...

13d ago

Promising Potential of Faron Pharmaceuticals’ Bexmarilimab in Treating High-Risk Myelodysplastic Syndromes and Solid Tumors Justifies Buy Rating

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy and keeping the price...

14d ago

Faron Pharmaceuticals Strengthens Financial Position with EUR 10 Million Bond Issuance

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an update. Faron Pharmaceuticals has issued a second tranche of...

19d ago

Promising Clinical Trial Results and Strategic Advancements Justify Buy Rating for Faron Pharmaceuticals

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Faron Pharmaceuticals Oy today and set a price...

22d ago

Faron Pharmaceuticals Registers New Shares Following Special Rights Exercise

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an announcement. Faron Pharmaceuticals Ltd has approved the exercise of...

27d ago

Faron Pharmaceuticals Approves New Share Issuance to Manage Convertible Bonds

An update from Faron Pharmaceuticals Oy ( ($GB:FARN) ) is now available. Faron Pharmaceuticals Ltd has approved the...

27d ago

Faron Pharmaceuticals Grants 180,000 Share Options

The latest update is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals Ltd has announced the...

28d ago

Faron Pharmaceuticals Announces Grant of 180,000 Share Options

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an announcement. Faron Pharmaceuticals Ltd announced the grant of 180,000...

28d ago

Faron Pharmaceuticals Appoints New CFO to Drive Growth

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals Ltd has appointed Jurriaan Dekkers as...

29d ago

Faron Pharmaceuticals Announces 2026 Financial Reporting Schedule

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals has announced its financial reporting dates...

1M ago

FARN FAQ

What was Faron Pharmaceuticals Oy’s price range in the past 12 months?

Faron Pharmaceuticals Oy lowest share price was 146.00p and its highest was 270.00p in the past 12 months.

What is Faron Pharmaceuticals Oy’s market cap?

Faron Pharmaceuticals Oy’s market cap is £195.43M.

When is Faron Pharmaceuticals Oy’s upcoming earnings report date?

Faron Pharmaceuticals Oy’s upcoming earnings report date is Mar 04, 2026 which is in 64 days.

How were Faron Pharmaceuticals Oy’s earnings last quarter?

Faron Pharmaceuticals Oy released its earnings results on Aug 27, 2025. The company reported -0.132p earnings per share for the quarter, beating the consensus estimate of -0.863p by 0.73p.

Is Faron Pharmaceuticals Oy overvalued?

According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faron Pharmaceuticals Oy pay dividends?

Faron Pharmaceuticals Oy does not currently pay dividends.

What is Faron Pharmaceuticals Oy’s EPS estimate?

Faron Pharmaceuticals Oy’s EPS estimate is -0.1.

How many shares outstanding does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy has 114,420,460 shares outstanding.

What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?

Faron Pharmaceuticals Oy reported an EPS of -0.132p in its last earnings report, beating expectations of -0.863p. Following the earnings report the stock price went down -4.494%.

Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?

Currently, no hedge funds are holding shares in GB:FARN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) Earnings & Revenues

Historic Earnings Reports

FARN Stock 12 Month Forecast

Average Price Target

1,000.00p

▲(488.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"169":"169p","377":"377p","585":"585p","793":"793p","1001":"1,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[169,377,585,793,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,190,252.30769230769232,314.61538461538464,376.9230769230769,439.2307692307692,501.53846153846155,563.8461538461538,626.1538461538462,688.4615384615385,750.7692307692307,813.0769230769231,875.3846153846154,937.6923076923076,{"y":1000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":180,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.5,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":170,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":209,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >